These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 8632421)

  • 1. Azole endothelin antagonists. 3. Using delta log P as a tool to improve absorption.
    von Geldern TW; Hoffman DJ; Kester JA; Nellans HN; Dayton BD; Calzadilla SV; Marsh KC; Hernandez L; Chiou W; Dixon DB; Wu-Wong JR; Opgenorth TJ
    J Med Chem; 1996 Feb; 39(4):982-91. PubMed ID: 8632421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Azole endothelin antagonists. 1. A receptor model explains an unusual structure-activity profile.
    von Geldern TW; Hutchins C; Kester JA; Wu-Wong JR; Chiou W; Dixon DB; Opgenorth TJ
    J Med Chem; 1996 Feb; 39(4):957-67. PubMed ID: 8632419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Azole endothelin antagonists. 2. Structure-activity studies.
    von Geldern TW; Kester JA; Bal R; Wu-Wong JR; Chiou W; Dixon DB; Opgenorth TJ
    J Med Chem; 1996 Feb; 39(4):968-81. PubMed ID: 8632420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absorption, distribution, metabolism, and excretion considerations in selection of orally active indole-containing endothelin antagonist.
    Walker DK; Dack KN; Dickinson RP; Fenner KS; James K; Rawson DJ; Smith DA
    Drug Metab Dispos; 2001 Nov; 29(11):1424-31. PubMed ID: 11602517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective antagonist.
    Murugesan N; Gu Z; Spergel S; Young M; Chen P; Mathur A; Leith L; Hermsmeier M; Liu EC; Zhang R; Bird E; Waldron T; Marino A; Koplowitz B; Humphreys WG; Chong S; Morrison RA; Webb ML; Moreland S; Trippodo N; Barrish JC
    J Med Chem; 2003 Jan; 46(1):125-37. PubMed ID: 12502366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pyrrolidine-3-carboxylic acids as endothelin antagonists. 2. Sulfonamide-based ETA/ETB mixed antagonists.
    Jae HS; Winn M; Dixon DB; Marsh KC; Nguyen B; Opgenorth TJ; von Geldern TW
    J Med Chem; 1997 Sep; 40(20):3217-27. PubMed ID: 9379441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective endothelin A receptor antagonists. 3. Discovery and structure-activity relationships of a series of 4-phenoxybutanoic acid derivatives.
    Astles PC; Brealey C; Brown TJ; Facchini V; Handscombe C; Harris NV; McCarthy C; McLay IM; Porter B; Roach AG; Sargent C; Smith C; Walsh RJ
    J Med Chem; 1998 Jul; 41(15):2732-44. PubMed ID: 9667964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of physicochemical and structural properties on the pharmacokinetics of a series of alpha1L-adrenoceptor antagonists.
    Betts A; Atkinson F; Gardner I; Fox D; Webster R; Beaumont K; Morgan P
    Drug Metab Dispos; 2007 Aug; 35(8):1435-45. PubMed ID: 17502340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effects of endothelin A and B receptor antagonism on fetal growth in normal and nitric oxide-deficient rats.
    Thaete LG; Neerhof MG; Silver RK
    J Soc Gynecol Investig; 2001; 8(1):18-23. PubMed ID: 11223352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological profile of ZD1611, a novel, orally active endothelin ETA receptor antagonist.
    Wilson C; Hunt SJ; Tang E; Wright N; Kelly E; Palmer S; Heys C; Mellor S; James R; Bialecki R
    J Pharmacol Exp Ther; 1999 Sep; 290(3):1085-91. PubMed ID: 10454481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and optimization of a novel class of orally active nonpeptidic endothelin-A receptor antagonists.
    Riechers H; Albrecht HP; Amberg W; Baumann E; Bernard H; Böhm HJ; Klinge D; Kling A; Müller S; Raschack M; Unger L; Walker N; Wernet W
    J Med Chem; 1996 May; 39(11):2123-8. PubMed ID: 8667356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery, modeling, and human pharmacokinetics of N-(2-acetyl-4,6-dimethylphenyl)-3-(3,4-dimethylisoxazol-5-ylsulfamoyl)thiophene-2-carboxamide (TBC3711), a second generation, ETA selective, and orally bioavailable endothelin antagonist.
    Wu C; Decker ER; Blok N; Bui H; You TJ; Wang J; Bourgoyne AR; Knowles V; Berens KL; Holland GW; Brock TA; Dixon RA
    J Med Chem; 2004 Apr; 47(8):1969-86. PubMed ID: 15055997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimation of blood levels of endothelin and neurokinin receptor antagonists at the rat portal and jugular veins after oral administration as a tool in peptide drug design.
    Paladino J; Kucharczyk N; Morris AD; Thibault-Naze M; Mahieu JP; Serkiz B; Volland JP; Autissier C; Fauchere JL
    Drug Des Discov; 1994 Nov; 12(2):121-8. PubMed ID: 9116167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological properties of J-104132 (L-753,037), a potent, orally active, mixed ETA/ETB endothelin receptor antagonist.
    Nishikibe M; Ohta H; Okada M; Ishikawa K; Hayama T; Fukuroda T; Noguchi K; Saito M; Kanoh T; Ozaki S; Kamei T; Hara K; William D; Kivlighn S; Krause S; Gabel R; Zingaro G; Nolan N; O'Brien J; Clayton F; Lynch J; Pettibone D; Siegl P
    J Pharmacol Exp Ther; 1999 Jun; 289(3):1262-70. PubMed ID: 10336515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2,4-Diarylpyrrolidine-3-carboxylic acids--potent ETA selective endothelin receptor antagonists. 1. Discovery of A-127722.
    Winn M; von Geldern TW; Opgenorth TJ; Jae HS; Tasker AS; Boyd SA; Kester JA; Mantei RA; Bal R; Sorensen BK; Wu-Wong JR; Chiou WJ; Dixon DB; Novosad EI; Hernandez L; Marsh KC
    J Med Chem; 1996 Mar; 39(5):1039-48. PubMed ID: 8676339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, and activity of a series of pyrrolidine-3-carboxylic acid-based, highly specific, orally active ET(B) antagonists containing a diphenylmethylamine acetamide side chain.
    Liu G; Kozmina NS; Winn M; von Geldern TW; Chiou WJ; Dixon DB; Nguyen B; Marsh KC; Opgenorth TJ
    J Med Chem; 1999 Sep; 42(18):3679-89. PubMed ID: 10479299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of a thieno[2,3-d]pyrimidine-2,4-dione bearing a p-methoxyureidophenyl moiety at the 6-position: a highly potent and orally bioavailable non-peptide antagonist for the human luteinizing hormone-releasing hormone receptor.
    Sasaki S; Cho N; Nara Y; Harada M; Endo S; Suzuki N; Furuya S; Fujino M
    J Med Chem; 2003 Jan; 46(1):113-24. PubMed ID: 12502365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-activity relationships of a novel class of endothelin receptor selective antagonists; 6-carboxy-2-isopropylamino-5,7-diarylcyclopenteno[1,2-b]pyridines.
    Takahashi H; Ohtake N; Sakamoto T; Iino T; Kawanishi N; Nakamura M; Yoshizumi T; Niiyama K; Ozaki S; Okada H; Kano A; Takahashi H; Ishii Y; Okada M; Saito M; Sawazaki Y; Hayama T; Nishikibe M
    Bioorg Med Chem Lett; 2004 Mar; 14(6):1503-7. PubMed ID: 15006391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-activity relationships of N2-aryl-3-(isoxazolylsulfamoyl)-2-thiophenecarboxamides as selective endothelin receptor-A antagonists.
    Wu C; Chan MF; Stavros F; Raju B; Okun I; Castillo RS
    J Med Chem; 1997 May; 40(11):1682-9. PubMed ID: 9171877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of endothelin receptor antagonists on myocardial protein kinase C isoforms in uraemic cardiomyopathy.
    Wolf SC; Amend T; Risler T; Amann K; Brehm BR
    Clin Sci (Lond); 2002 Aug; 103 Suppl 48():276S-279S. PubMed ID: 12193103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.